GlassScriptPhysician profile
Jeffrey Siegel
NPI 1952332132
$2,401.00
in general payments reported to CMS, 2019-2025
28 companies · $19.11 in 2025
The $19.11 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $94.16 · 2021: $299 · 2022: $966 · 2023: $762 · 2024: $261 · 2025: $19.11.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,042.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,041.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Valencia Technologies Corporation | $851.77 | 2022 | |
| Abbvie INC. | $407.89 | 2021-2025 | Ubrelvy, Duopa, Qulipta |
| Emd Serono, INC. | $166.16 | 2019-2023 | Mavenclad |
| Novartis Pharmaceuticals Corporation | $123.46 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $104.31 | 2023 | Rexulti |
| Biogen, INC. | $68.75 | 2021 | |
| Neurelis, INC. | $65.35 | 2023-2024 | Valtoco |
| Lundbeck LLC | $64.32 | 2022-2024 | Vyepti |
| Eisai INC. | $54.17 | 2023-2024 | |
| Si-Bone, INC. | $45.57 | 2023-2024 | |
| Biohaven Pharmaceuticals, INC. | $41.64 | 2021 | |
| Tg Therapeutics, INC. | $35.81 | 2023-2024 | |
| Lilly USA, LLC | $34.78 | 2019-2024 | Amyvid |
| Takeda Pharmaceuticals U.S.A., INC. | $32.30 | 2024 | Hyqvia |
| Alexion Pharmaceuticals, INC. | $32.16 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $30.44 | 2022 | |
| Kyowa Kirin, INC. | $28.99 | 2022 | |
| Pfizer INC. | $24.62 | 2023 | |
| Abbott Laboratories | $22.50 | 2023 | Infinity |
| Baxter Healthcare | $21.80 | 2023 | Floseal |
| Sk Life Science, INC. | $21.18 | 2023 | |
| Mdd US Operations, LLC | $20.95 | 2022 | |
| Argenx US, INC. | $20.27 | 2023 | Vyvgart Hytrulo |
| Amgen INC. | $19.41 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $16.89 | 2019 | |
| Ge Healthcare | $15.43 | 2019 | |
| Jazz Pharmaceuticals INC. | $15.41 | 2024 | |
| Tanabe Pharma America, INC. | $14.67 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Siegel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.